STAT Plus: As biotech drifts from amyloid hypothesis for Alzheimer’s, some see reason to cling on

Two biotech CEOs are cautiously optimistic about the controversial amyloid hypothesis, which suggests a sticky brain plaque causes Alzheimer’s — a departure from most of the rest of the industry, which has largely abandoned the theory, once dogma, after a long string of clinical trial failures.

But Susan Catalano, the co-founder and CSO of Cognition Therapeutics, said her company is still indirectly targeting it for drug development, in part because she thinks other researchers didn’t appreciate the different forms the plaque-forming substance can take.

Continue to STAT Plus to read the full story…